This study is for adults with advanced solid tumors containing a specific gene change called KRAS G12C mutation. These tumors are either metastatic (spread to other parts of the body) or unresectable (cannot be surgically removed). The study has two parts: Phase Ib and Phase II. In the first part, doctors will check how safe and tolerable the new drug JDQ443 is, alone and with other treatments called TNO155 and tislelizumab. In the second part, they will test how well the treatments work against tumors.

To join, you need a good performance status (able to take care of yourself) and at least one tumor that can be measured. If you’ve already tried a KRAS G12C inhibitor, you might still join some parts of the study. You cannot join if you have other types of tumors with known treatments, certain brain issues, or heart problems.

• Eligibility: Adults with KRAS G12C mutation.
• Study Length: Depends on response and tolerance.
• Risks: Possible side effects from the drugs.